Table of contents
About this book
Plants such as Catharanthus roseus, Podophyllum peltatum, Taxus brevifolia, Camptotheca acuminate, Andrographis paniculata, Crateva nurvala, Croton tonkinensis, Oplopanax horridus etc., are important source of chemotherapeutic compounds. These plants have proven their value in the treatment of cancer and various other infectious diseases, and several common anticancer compounds such as taxol, podophyllotoxins, camptothecin, vinblastine, vincristine, homoharringtonine etc. have been isolated and purified from these medicinal plants.
Unfortunately, many of these anticancer plants have become endangered due to ruthless and irresponsible harvesting practices. Hence, there is a need to conserve these species and to propagate them on a large scale using plant tissue culture. Alternatively, plant cell tissue and organ culture biotechnology could be adopted to produce these anticancer compounds without the need for cultivation. A better grasp and continuing exploration of these isolated molecules and products could provide a powerful alternative means of reducing cancer risk.
“Anticancer Plants: Volume 3, Clinical Trials and Nanotechnology” provides a timely review of concepts and experimental data on the application of anticancer plants and their compounds in clinical trials, and on the use of nanotechnology in cancer therapy.
Editors and affiliations
- DOI https://doi.org/10.1007/978-981-10-8216-0
- Copyright Information Springer Nature Singapore Pte Ltd. 2017
- Publisher Name Springer, Singapore
- eBook Packages Biomedical and Life Sciences
- Print ISBN 978-981-10-8215-3
- Online ISBN 978-981-10-8216-0
- Buy this book on publisher's site